These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8489554)

  • 1. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
    Clemens JA; Okimura T; Smalstig EB
    Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
    Wong DT; Threlkeld PG; Bymaster FP
    Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area.
    Zhang XX; Jin GZ; Wei YF
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):423-7. PubMed ID: 8701759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography.
    Trugman JM; Arnold WS; Touchet N; Wooten GF
    J Pharmacol Exp Ther; 1989 Sep; 250(3):1156-60. PubMed ID: 2674418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
    Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A
    Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist.
    Foreman MM; Fuller RW; Hynes MD; Gidda JS; Nichols CL; Schaus JM; Kornfeld EC; Clemens JA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):227-35. PubMed ID: 2526214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
    Sprah L; Zivin M; Sket D
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
    Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
    Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral characterization of the new potent nonselective dopamine agonist pergolide.
    Helton DR; Modlin DL; Williams PD
    Arzneimittelforschung; 1992 Jul; 42(7):885-90. PubMed ID: 1418051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
    McPherson RJ; Marshall JF
    Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.
    Felten DL; Felten SY; Fuller RW; Romano TD; Smalstig EB; Wong DT; Clemens JA
    Neurobiol Aging; 1992; 13(2):339-51. PubMed ID: 1381815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolite involvement in bromocriptine-induced prolactin inhibition in rats.
    Valente D; Delaforge M; Urien S; Guivarc'h D; Vienet R; Grognet JM; Ezan E
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1418-24. PubMed ID: 9316855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.
    Asanuma M; Ogawa N; Nishibayashi S; Kawai M; Kondo Y; Iwata E
    Arch Int Pharmacodyn Ther; 1995; 329(2):221-30. PubMed ID: 8540762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
    Belluzzi JD; Domino EF; May JM; Bankiewicz KS; McAfee DA
    Mov Disord; 1994 Mar; 9(2):147-54. PubMed ID: 7910948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General pharmacology of pergolide in animals. 1st communication: cardiovascular, respiratory and autonomic nervous system studies.
    Williams P; Colbert W; Turk J; Owen N
    Arzneimittelforschung; 1992 May; 42(5):599-607. PubMed ID: 1530670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N; Mizuta E; Yoshida O; Kuno S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
    Koller W; Herbster G; Gordon J
    Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    de Yebenes JG; Fahn S; Lovelle S; Jackson-Lewis V; Jorge P; Mena MA; Reiriz J; Bustos JC; Magariños C; Martinez A
    Mov Disord; 1987; 2(3):143-58. PubMed ID: 2904648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.